Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Conditions: Head and Neck Cancer; Relapse; Recurrent; Refractory Cancer Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Cell Therapy Sponsors: UNC Lineberger Comprehensive Cancer Center; Bellicum Pharmaceuticals; University Cancer Research Fund at Lineberger Comprehensive Cancer Center Not yet recruiting

https://clinicaltrials.gov/study/NCT06096038

Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials

More News: Cancer | Cancer & Oncology | Head and Neck Cancer | HNSCC | Research